G. Yancey Gillespie

G. Yancey Gillespie

Auto-generated profile, based on publicly available information

G. Yancey Gillespie

Department of Neurosurgery

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2002
Verified
Journal Article
Closed access
CCCharles S Cobbs
Charles S Cobbs
LHLualhati Harkins
Lualhati Harkins
MSMinu Samanta
Minu Samanta
GGG Yancey Gillespie
G Yancey Gillespie
SBSuman Bharara
Suman Bharara
WBWilliam J Britt
William J Britt

21 December 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
NBNathaniel H. Boyd
Nathaniel H. Boyd
Kiera WalkerKiera Walker
Kiera Walker
JFJoshua Fried
Joshua Fried
JHJames R. Hackney
James R. Hackney
PMPaul C. McDonald
Paul C. McDonald
AHAnita Hjelmeland
Anita Hjelmeland
Tumor microenvironments can promote stem cell maintenance, tumor growth, and therapeutic resistance, findings linked by the tumor-initiating cell hypothesis. Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs). Temozolomide efficacy may be increased by targeting carbonic anhydrase 9 ( CA9 ), a hypoxia-responsive gene important for maintaining the altered pH gradient of tumor cells. Using patient-derived GBM xenograft cells, we explored whether CA9 and CA12 inhibitor SLC-0111 could decrease GBM growth in combination with temozolomide or influence percentages of BTICs after chemotherapy. In multiple GBMs, SLC-0111 used concurrently with temozolomide reduced cell growth and induced cell cycle arrest via DNA damage in vitro. In addition, this treatment shifted tumor metabolism to a suppressed bioenergetic state in vivo. SLC-0111 also inhibited the enrichment of BTICs after temozolomide treatment determined via CD133 expression and neurosphere formation capacity. GBM xenografts treated with SLC-0111 in combination with temozolomide regressed significantly, and this effect was greater than that of temozolomide or SLC-0111 alone. We determined that SLC-0111 improves the efficacy of temozolomide to extend survival of GBM-bearing mice and should be explored as a treatment strategy in combination with current standard of care.

1 July 2005 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
EHElizabeth K. Hellums
Elizabeth K. Hellums
JMJames M. Markert
James M. Markert
JPJacqueline N. Parker
Jacqueline N. Parker
BHBin He
Bin He
BPBernard Perbal
Bernard Perbal
GGG. Yancey Gillespie
G. Yancey Gillespie
Long-term survivors of glioblastoma multiforme, the most common form of primary intracranial malignancy in adults, are extremely rare. Experimental a

14 January 2011 in Cancers
Verified
Journal Article
Open access
PDF file
GFGregory Friedman
Gregory Friedman
GGG. Yancey Gillespie
G. Yancey Gillespie
Recently, a subpopulation of cells, termed tumor-initiating cells or tumor stem cells (TSC), has been identified in many different types of solid tumors. These TSC, which are typically more resistant to chemotherapy and radiation compared to other tumor cells, have properties similar to normal stem cells including multipotency and the ability to self-renew, proliferate, and maintain the neoplastic clone. Much of the research on TSC has focused on adult cancers. With considerable differences in tumor biology between adult and pediatric cancers, there may be significant differences in the presence, function and behavior of TSC in pediatric malignancies. We discuss what is currently known about pediatric solid TSC with specific focus on TSC markers, tumor microenvironment, signaling pathways, therapeutic resistance and potential future therapies to target pediatric TSC.

1 November 2006
Verified
Journal Article
Closed access
JMJames M Markert
James M Markert
JPJacqueline N Parker
Jacqueline N Parker
DBDonald J. Buchsbaum
Donald J. Buchsbaum
WGWilliam E Grizzle
William E Grizzle
GGG Yancey Gillespie
G Yancey Gillespie
RWRichard Whitley
Richard Whitley

21 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GDG. Clement Dobbins
G. Clement Dobbins
HUHideyo Ugai
Hideyo Ugai
DCDavid T. Curiel
David T. Curiel
GGG. Yancey Gillespie
G. Yancey Gillespie
Studies have demonstrated that oncolytic adenoviruses based on a 24 base pair deletion in the viral E1A gene (D24) may be promising therapeutics for treating a number of cancer types. In order to increase the therapeutic potential of these oncolytic viruses, a novel conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in all tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was then engineered to deliver immunotherapeutic agents such as GM-CSF while maintaining enhanced heterogenic oncolysis.